Tampa, Fla. and Baltimore, Md. (Vocus) April 15, 2010
PMSI, one of the nation’s largest providers of specialty products and services for the workers’ compensation market, and Ameritox, the nation’s leader in pain medication monitoring solutions, today announced a strategic partnership to monitor and promote the appropriate use of opioid medications by injured workers.
“The use of opioid analgesics is extremely prevalent in the workers’ compensation population, with nearly 70% of injured workers taking opioids to control pain,” stated Maria Sciame, PharmD, PMSI’s executive director of clinical services. “However, when chronic pain is evident, prescribers frequently order opioids with other related medications which can result in overuse of medications. Additionally, there is potential for fraud and abuse in use of opioids through drug diversion or misuse.”
Historically, it has been difficult to identify which injured workers may be abusing or misusing controlled substances or illicit drugs. The PMSI MedAssessTM Care Management Program, a new drug testing and monitoring service, identifies at-risk individuals and facilitates urine drug testing at the prescriber level.
“The American Pain Society and American Academy of Pain Medicine guidelines recommend using periodic urine drug testing for patients at risk for abuse,” stated Eileen Auen, PMSI’s chief executive officer. “As leaders in the industry, PMSI and Ameritox have worked together to develop a customized program to facilitate this recommended testing. The combination of PMSI’s clinical expertise with Ameritox’s superior urine drug monitoring solutions provides an integrated program unlike any other in the industry.”
“PMSI and Ameritox are providing the workers’ compensation industry with a patient-centered program that helps clinicians maximize patient care while also addressing potential opioid fraud and abuse,” said Ancelmo Lopes, chief executive officer of Ameritox. “By capturing patient medication history, communicating with claims adjusters and case managers, helping physicians to identify appropriate follow-up measures and providing on-going monitoring, we are better able to enhance the quality and cost effectiveness of chronic opioid therapy.”
PMSI is one of the nation’s largest full-service providers of clinically driven services for Pharmacy, Medical Services and Equipment, and Settlement Solutions and is devoted exclusively to the workers’ compensation and liability markets. For over 34 years, PMSI has led the industry and served as the trusted resource for thousands of insurance payers, state workers’ compensation funds, employers, and third-party administrators. Today, PMSI continues its leadership position by managing millions of pharmacy, medical services and equipment, and settlement transactions each year. For more information, please refer to the PMSI website at http://www.pmsionline.com .
Ameritox is the nation’s leader in pain medication monitoring solutionsSM, offering specialized laboratory testing and reporting services. Ameritox’s expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers Rx GuardianSM, the most thorough and personalized lab service available and the only pain medication monitoring program with a proprietary methodology to help physicians assess whether patients are taking their pain medication as directed. Medication monitoring helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore with laboratory facilities in Midland, Texas and Greensboro, N.C. For more information about pain medication monitoring, please refer to http://www.ameritox.com .
Executive Director, Marketing
Edelman Public Relations